As of May 21
| -0.05 / -1.36%|
The 1 analysts offering 12-month price forecasts for TapImmune Inc have a median target of 5.50, with a high estimate of 5.50 and a low estimate of 5.50. The median estimate represents a +51.10% increase from the last price of 3.64.
The current consensus among 1 polled investment analysts is to Outperform stock in TapImmune Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.